 |
 |
| |
Novartis AG, Pfizer Inc., and
GlaxoSmithKline plc have won top honors in the first-ever study of
the corporate reputation strength of major pharmaceutical companies
in Europe. Read latest
release |
| |
|
|
| |
New ethics study reveals a "high
quality" image as rating upgrades balance downgrades
although consumer confidence remains a serious issue. Read
release and rating table |
| |
|
|
| |
Most of the pharmaceutical industry's
ethical gains are lost on the general public, according to the latest
reputation research by RRC. Link to the full article in Pharmaceutical Executive. |
| |
|
|
| |
Big pharmas lose ground, as fast-moving
biotechs shoot to the top. Five firms, including Merck and Pfizer,
downgraded. Genentech, Novartis, Roche move higher. J&J retains
sole AAA. Read release and rating change table. |
| |
|
|
| |
RRC polls reveal dramatic shifts
in perceptions of CEO effectiveness. Changes reflect challenges of
Cox-2 inhibitor risk, adverse public opinion, and a host of other
issues. See changes in pharma CEO rankings 2003 to 2005. |
| |
|
|
| |
RRC’s Jeff Resnick and Dory
Gasorek drill down into detailed results of our latest study of the
pharma industry reputation risk as viewed by industry insiders and
financial analysts. Link to full article. |
| |
|
|
| |
Senior executives of US drug companies
have a high opinion of their ethics, but the American public thinks
just the opposite. This according to the latest polls by RRC and
affiliate Opinion Research Corporation. More. |
| |
|
| |
Reputation ratings of seven US
utilities downgrade, four upgraded. Read in-depth report of RRC electric
power industry research. |
| |
| |
|
|
|
“Corporate reputation
should be considered as much more than simply a brand emblem in the
marketplace. Rather, it is a window to the fundamental character of
a company and its leaders and as such is relevant to all stakeholders…”
— Professor Stephen A. Greyser, Harvard Business School
Rating Research LLC (RRC) is a public
rating agency that measures the critical intangible assets that constitute
corporate reputation. RRC’s broadly disseminated Reputation
Ratings and Ethics Reputation Ratings
on leading companies — and the Industry
Reputation Studies that support and explain those ratings —
provide interested third parties, relevant stakeholders, and the general
public with greater insight into corporations’ performance –
both present and future.
Recent events have dramatically increased the demand for independent
and objective analysis and opinion about the reputations of leading
corporations. Increasingly, a company’s reputation is being recognized
as a strategic asset with a direct impact on that company’s long-term
financial health. RRC believes that the adoption and use of its Reputation
Ratings by rated companies, business and financial media, consumers,
investors, regulators, and the financial community, among others, will
encourage greater corporate accountability and transparency.
For more background on RRC, visit Profile.
For in-depth analysis of particular industries, historical trend analysis
or companies' ratings, RRC provides a variety of Products.
| RRC's reputation ratings and ethics reputation
ratings are, and must be construed solely as, statements of opinion
and not statements of fact or recommendation to purchase, sell or
hold any securities. As a matter of policy, RRC does not provide
investment advice to any person or entity. |
|
